The German pharmaceutical multinational corporation, Boehringer Ingelheim, intends to test IBM's blockchainBlockchain
is a continuous and sequential block chain of information (digital linked list). When building a blockchain, copies of related blocks are simultaneously stored on multiple computers.Details in Canada to "improve the quality of clinical trials," as reported by CoinDesk.
On Tuesday, February 12th, the Boehringer Ingelheim company (Canada) published a message on collaboration with IBM "in orderOrder
– automatic application to buy or sell cryptocurrency. Orders are used during trading on the stock exchange to open and close a position. Details to increase trust, transparency, patient safety, empower patients in clinical trials."
Interesting in the section: 0x: development and prospects
IBM Blockchain and pharmaceuticals
The Boehringer Ingelheim company stated that the goal of implementing blockchain technology is to solve the problems of the quality of research and clinical trial records. According to a Boehringer report, currently documentation is often "incomplete and patterned" and can compromise patient safety.
According to the project’s press-release, the blockchain will help create a decentralized structure that preserves "the integrity of the data, ensures transparency and allows automating the processes". Dr. Uli Brödl, vice president of health and regulatory affairs at Boehringer Ingelheim (Canada), commented on the introduction of blockchain-innovation.
"The clinical trial ecosystem is very complex because it involves various stakeholders, which leads to limited trust, lack of transparency and low process efficiency (...) The modern clinical research system works without real empowering patients" – Dr. Uli Brödl.
Claude Guay, IBM's general service manager, also commented on the collaboration: "We have already used blockchain in various industries (...) now we are exploring how this technology can be used to give Canadian patients a high level of security and trust to work with their personal health information."
Interesting in the section: Blokchain technology outside cryptocurrencies
A German pharmaceutical company has announced the use of the IBM blockchain to work effectively with clinical research in Canada. Recall that other major pharmaceutical companies are also exploring the potential benefits of integrating blockchain technology. In January 2018, Pfizer, Amgen and Sanofi also looked at the blockchain to optimize the process of developing and testing new drugs.
Editor: Alyona Nabok